H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $5.00 price target on BioXcel Therapeutics (NASDAQ: BTAI).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments